Combination of TCBs with anti-PD-L1 blocking antibody (in different tumor and mouse models and using different TCBs targeting both CEA (solid tumors) and CD20 (hematological malignancies) consistently translated into superior anti-tumor efficacy and stronger tumor growth inhibition when compared to either agent given as monotherapy. The gene discussed is KRT20; the disease is hematologic disorder.